Senseonics to Regain Commercial Control of Eversense 365 CGM

Senseonics has obtained FDA clearance for its year-long continuous glucose monitoring (CGM) system and plans to take back commercialization and distribution responsibilities from Ascensia Diabetes Care starting in 2026. Since 2020, Ascensia has been the exclusive global distributor of Eversense devices, allowing Senseonics to avoid the cost of establishing its own sales network, though at the expense of revenue sharing.

With the transition, Senseonics anticipates gross margins will rise from about 35% in 2025 to 50% by 2026, and potentially reach 70% over time. However, analysts at BTIG noted the company must weigh additional expenses tied to building a commercial infrastructure. The move highlights Senseonics’ confidence that its 365-day Eversense implant will spark increased demand. By offering a longer lifespan compared to earlier models, the device positions the company to challenge established CGM leaders Abbott and Dexcom in the competitive U.S. diabetes market.

22-09-2025